Share This Article:

Risk of Second Solid Malignancy among 1000 Kidney Transplanted Patients: A Single Center Study

Full-Text HTML XML Download Download as PDF (Size:120KB) PP. 42-45
DOI: 10.4236/ojots.2012.24011    3,638 Downloads   5,809 Views  

ABSTRACT

In this study we focus on kidney-transplanted patients in order to investigate the correlation between immunodeficiency (ID) induced by immunosuppressive treatments and the incidence of solid multiple primary malignancies (MPM). Material of study: From 1980 to 2010 we followed up 1000 kidney-transplanted patients (637M, 363F). This group was homogeneous for age, immunology (e.g. miss-match index), number of rejection events and for immunosuppressive therapy. Results: Out of 1000 kidney-transplanted patients we observed 70 patients (53M, 17F) with cancer disease and in 22 of them a multiple cancer has been found. Most of multiple cancer were synchronous and the association between cancer and rejection episodes were not significant. Discussion: In general population 1 out of 9 patients with a cancer would develop a second neoplasia during the course of his life, so, it would be logical to conclude that, from a merely theoretical and statistical point of view, long term transplanted patients potentially have a higher risk to develop MPM. But our series and literature review did not confirm it, probably because these patients die before the appearance of a second primary malignancy. Conclusions: Despite many observations regarding different types of tumors/pre-cancerous lesions and their increased incidence in ID patients and despite the fact that immune suppression is a predisposing factor for the multicancer syndrome, at least theoretically, nowadays there are no significant statistical data favouring a correlation between ID and MPM in kidney transplanted patients.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Santangelo, M. , Spiezia, S. , Carlomagno, N. , Dodaro, C. , Tessa, C. , Rosa, D. , Piantadosi, M. and Renda, A. (2012) Risk of Second Solid Malignancy among 1000 Kidney Transplanted Patients: A Single Center Study. Open Journal of Organ Transplant Surgery, 2, 42-45. doi: 10.4236/ojots.2012.24011.

References

[1] A. Piro, A. Tagarelli, G. Tagarelli, P. Lagonia and A. Quattrone, “Paul Ehrlich: The Nobel Prize in Physiology or Medicine 1908,” International Reviews of Immunology, Vol. 27, No. 1-2, 2008, pp. 1-17. doi:10.1080/08830180701848995
[2] A. Renda and N. Carlomagno, “Nosography in: A. Renda (Ed): Multiple Primary Malignancies,” Springer Press, Milan, 2009, pp. 1-6.
[3] A. Picascia, P. Giannattasio, V. Grimaldi, et al., “Preliminary Analysis of Kidney Transplantation in Naples from 2000 to 2006,” Tissue Antigens, Vol. 79, No. 6, 2012, p. 502.
[4] V. Grimaldi, A. Picascia, P. Giannattasio, et al., “Kidney Transplantation and Immunohematological Profile in Naples: A Coordinating Regional Experience from 2000 to 2006,” Vox Sanguinis, Vol. 103, No. 1, 2012, p. 269.
[5] J. Chinen, D. Anmuth, A. R. Franklin and W. T. Shearer, “Long-Term Follow-Up of Patients with Primary Immunodeficiencies,” Journal of Allergy and Clinical Immunology, Vol. 120, No. 4, 2007, pp. 795-797. doi:10.1016/j.jaci.2007.07.044
[6] P. De Rosa, M. Santangelo, A. Ferrara, et al., “Suboptimal Kidney: The Experience of a Single Transplant Unit,” Transplantation Proceedings, Vol. 36, No. 3, 2004, pp. 488-490. doi:10.1016/j.transproceed.2004.02.008
[7] M. Santangelo, P. De Rosa, S. Spiezia, et al., “Healing of Surgical Incision in Kidney Transplantation: A Single Transplant Center’s Experience,” Transplantation Proceedings, Vol. 38, No. 4, 2006, pp. 1044-1046. doi:10.1016/j.transproceed.2006.03.005
[8] P. De Rosa, M. Santangelo, A. Scala, et al., “Difficult Vascular Conditions in Kidney Transplantation,” Transplantation Proceedings, Vol. 38, No. 4, 2006, pp. 1040-1043 doi:10.1016/j.transproceed.2006.03.073
[9] M. Santangelo, M. Zuccaro, P. De Rosa, et al., “Older Kidneys Donor Transplantation: Five Years’ Experience without Biopsy and Using Clinical Laboratory and Macroscopic Anatomy Evaluation,” Transplantation Proceedings, Vol. 39, No. 6, 2007, pp. 1835-1837. doi:10.1016/j.transproceed.2007.05.039
[10] M. Santangelo, M. Clemente, S. Spiezia, et al., “Wound Complications after Kidney Transplantation in Nondiabetic Patients,” Transplantation Proceedings, Vol. 41, No. 4, 2009, pp. 1221-1223. doi:10.1016/j.transproceed.2009.03.098
[11] IARC, “Epstein-Barr Virus and Kaposi’s Sarcoma Herpesvirus/Human Herpesvirus 8,” In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, World Health Origination International Agency for Research on Cancer Press, Lyon, 1997, p. 70.
[12] EBPG Expert Group on Renal Transplantation, “European Best Practice Guidelines for Renal Transplantation,” Section IV: Long-Term Management of the Transplant Recipient, Nephrology Dialysis Transplantation, Vol. 17, No. 4, 2002, pp. 1-67. doi:10.1093/ndt/17.suppl_4.1-a
[13] A. G. Sheil, “Organ Transplantation and Malignancy: Inevitable Linkage,” Transplantation Proceeding, Vol. 34, No. 6, 2002, pp. 2436-2437. doi:10.1016/S0041-1345(02)03169-X
[14] A. Gutierrez-Dalmau and J. M. Campistol, “Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients: A Systematic Review,” Drugs, Vol. 67, No. 8, 2007, pp. 1167-1198. doi:10.2165/00003495-200767080-00006
[15] M. Santangelo, S. Spiezia, M. Clemente, et al., “Immunodeficiency and Multiple Primary Malignancies in: A. Renda (Ed): Multiple Primary Malignancies,” Springer Press, Milan, 2009, pp. 83-96.
[16] P. O’Donovan, C. M. Perrett, X. Zhang, B. Montaner, et al., “Azathioprine and UVA Light Generate Mutagenic Oxidative DNA Damage,” Science, Vol. 309, No. 5742, 2005, pp. 1871-1874. doi:10.1126/science.1114233
[17] S. R. Rheingold, A. I. Neugut and A. T. Meadows, “Secondary Cancer: Incidence, Risk Factors and Management,” In: E. Frey, Ed., Holland-Frei Cancer Medicine, BC Decker Press, Hamilton, 2000.
[18] E. Strocchi, R. V. Iaffaioli, G. Facchini, et al., “Stop-Flow Technique for Loco-Regional Delivery of High Dose Chemotherapy in the Treatment of Advanced Pelvic Cancers,” European Journal of Surgical Oncology, Vol. 30, No. 6, 2004. pp. 663-670. doi:10.1016/j.ejso.2004.04.005
[19] P. Piscicelli, A. Santoriello, F. M. Buonaguro, et al., “Incidence of Breast Cancer in Italy: Mastectomies and Quadrantectomies Performed between 2000 and 2005,” Journal of Experimental and Clinical Cancer Research, Vol. 28, No. 1, 2009, p. 86. doi:10.1186/1756-9966-28-86
[20] L. Insabato, M. Siano, A. Somma, et al., “Extrapleural Solitary Fibrous Tumor: A Clinicopathologic Study of 19 Cases,” International Journal of Surgical Pathology, Vol. 17, No. 3, 2009, pp. 250-254. doi:10.1177/1066896909333779
[21] A. Tortoriello, G. Facchini, F. Caponigro, et al., “Phase I/II Study of Paclitaxel and Vinorelbine in Metastatic Breast Cancer,” Breast Cancer Research and Treatment, Vol. 47, No. 1, 1998, pp. 91-97. doi:10.1023/A:1005848921895
[22] H. M. Kauffman, W. S. Cherick, M. A. McBride, Y. Cheng and D. W. Hanto, “Deceased Donors with a Past History of Malignancy: An Organ Procurement and Transplantation Net Work/United Network for Organ Sharing Update,” Transplantation, Vol. 84, No. 2, 2007, pp. 272-274. doi:10.1097/01.tp.0000267919.93425.fb
[23] S. Maurea, M. Fusari, M. Imbriaco, et al., “Pitfalls in Diagnostic Imaging of Cystic Pancreatic Masses: A Case of True Cystic Lesion Mimicking a Mucinous Cystadenoma,” Journal of the Pancreas, Vol. 13, No. 1, 2012, pp. 83-86
[24] J. Dantal and E. Pohanka, “Malignancies in renal Transplantation: An Unmet Medical Need,” Nephrology Dialysis Transplantation, Vol. 22, No. 1, 2007, pp. 4-10. doi:10.1093/ndt/gfm085

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.